#ЕУзаТебе

D-LLIFE: Innovative solutions in medicine

Intermedic Group and the Vinča Institute develop advanced solutions for modern medicine

Fluid accumulation in the lungs is one of the most common and deadliest complications in patients with heart failure. Although this condition can be treated, timely diagnosis remains the main challenge, as patients often seek medical attention only when symptoms become severe, making treatment more complex and less effective.

To address this issue, the team at Intermedic Group has developed an innovative solution, D-LIFE, a mobile bioimpedance monitor capable of detecting the presence and amount of fluid in the lungs before symptoms appear. This device enables doctors and patients to respond in a timely manner, reduces the risk of serious complications, and has the potential to save thousands of lives each year.

"Fluid accumulation in the lungs often develops silently and without clear symptoms until it becomes critical. D-LIFE enables early detection and timely therapy, saving lives and significantly reducing treatment costs," emphasized Jovana Petrović from Intermedic Group.

From Scientific Research to Medical Application

D-LIFE is the result of years of research and development, based on expertise in the field of mobile diagnostic devices at the Vinča Institute. It originates from the work of researchers and engineers, who have refined the methods of noninvasive measurements of the physiological functions and processes, in this case the fluid content of lungs, with the goal of their applications in medical diagnostics.

By combining advanced sensors and algorithms, the team has developed a device that can accurately and quickly assess changes in fluid levels in the lungs, giving patients and doctors valuable time to respond before the condition becomes critical.

"The biggest challenge we faced was clinical testing as the devices must undergo strict medical verification before they reach patients." "That is why the collaboration with doctors who are interested in innovations was key to our success," explains Petrović.

A Step Toward Commercialization with the Support of the Innovation Activity Fund

The development of a medical device is a technical challenge, but also a long and complex process of testing, certification, and patent protection. Intermedic Group, with the financial support of the Innovation Activity Fund and the European Union, was able to secure the technical development of the device, initial clinical testing, and a patent application, which is the first major step toward commercialization.

"The Fund's investment enabled us not only to develop the device but also to go through the key testing phases necessary for D-LIFE to become available to patients worldwide," emphasizes Mirjana Stojanović (Research Associate at INN Vinča).

The Future of Personalized Diagnostics

What makes D-LIFE unique is its ability to enable timely intervention for patients and doctors before the disease reaches a critical stage. With applications in hospitals, clinics, and home settings, this device opens the door to a new era of personalized medicine, where early signs of deterioration can be detected and treated in time.

In the next steps, Intermedic Group is focusing on further clinical testing, obtaining regulatory approvals, and entering the global market, where D-LIFE has the potential to become the standard in preventing complications in patients with heart failure.